Literature DB >> 7831531

The classification of ductal carcinoma in situ and its association with biological markers.

L G Bobrow1, L C Happerfield, W M Gregory, R D Springall, R R Millis.   

Abstract

One hundred five cases of pure ductal carcinoma in situ (DCIS) seen in the Guys Hospital breast unit between 1975 and 1991 were reviewed and reclassified using a modified histologic classification based on cytological features as well as histological architecture. The expression of p53 protein, cerbB2 protein, progesterone receptor, and a proliferation antigen KiS1, all factors reported to be of prognostic significance in invasive ductal carcinoma, was also evaluated using immunohistochemical methods. The mode of presentation of these cases was noted, and its relationship to biological markers and histologic type was also assessed. Good interobserver agreement was achieved by two independent observers using the modified histologic classification. Strong correlation was seen between histologic pattern and biological markers as well as between the individual markers. Poorly differentiated DCIS was associated with a high proliferation rate, the presence of cerbB2 and p53 protein and the absence of progesterone receptors. Well-differentiated DCIS showed the reverse, and the intermediate group showed an intermediate pattern. Paget's disease of the nipple was only seen in association with poorly differentiated DCIS, but no other significant association was noted between mode of presentation and DCIS type.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7831531

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  18 in total

1.  Immunohistochemical localization of Bcl-2 and Bax proteins in in situ and invasive duct breast carcinomas.

Authors:  N Kapucuoglu; L Losi; V Eusebi
Journal:  Virchows Arch       Date:  1997-01       Impact factor: 4.064

2.  Cytological and architectural heterogeneity in ductal carcinoma in situ of the breast.

Authors:  C M Quinn; J L Ostrowski
Journal:  J Clin Pathol       Date:  1997-07       Impact factor: 3.411

3.  C-Erb-b2 oncogene expression in intraductal proliferative lesions of the breast.

Authors:  Filiz Eren; Zerrin Calay; Haydar Durak; Bülent Eren; Nil Comunoğlu; Ovgü Aydin
Journal:  Bosn J Basic Med Sci       Date:  2012-02       Impact factor: 3.363

4.  An immunohistochemical study of the expression of bcl-2 and p53 oncoproteins in pancreatic intraepithelial neoplasia and pancreatic cancer.

Authors:  R Tomaszewska; D Karcz; J Stachura
Journal:  Int J Pancreatol       Date:  1999-12

Review 5.  Is DCIS breast cancer, and how do I treat it?

Authors:  N Bijker; M Donker; J Wesseling; G J den Heeten; E J Th Rutgers
Journal:  Curr Treat Options Oncol       Date:  2013-03

6.  Human fatty acid synthase: structure and substrate selectivity of the thioesterase domain.

Authors:  Bornali Chakravarty; Ziwei Gu; Subrahmanyam S Chirala; Salih J Wakil; Florante A Quiocho
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-26       Impact factor: 11.205

Review 7.  Biological features of premalignant disease in the human breast.

Authors:  D C Allred; S K Mohsin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

8.  A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial.

Authors:  S E Pinder; C Duggan; I O Ellis; J Cuzick; J F Forbes; H Bishop; I S Fentiman; W D George
Journal:  Br J Cancer       Date:  2010-06-01       Impact factor: 7.640

Review 9.  The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.

Authors:  Jaclyn A Freudenberg; Qiang Wang; Makoto Katsumata; Jeffrey Drebin; Izumi Nagatomo; Mark I Greene
Journal:  Exp Mol Pathol       Date:  2009-05-18       Impact factor: 3.362

10.  Reproducibility of new classification schemes for the pathology of ductal carcinoma in situ of the breast.

Authors:  P Bethwaite; N Smith; B Delahunt; D Kenwright
Journal:  J Clin Pathol       Date:  1998-06       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.